ATNM:Actinium Pharmaceuticals Inc Snapshot | Charting | News | Options
$6.96 NYSE MKT LLC 8:01a ET
April 18 '24 		Actinium Highlights Ability of Iomab-B to Overcome High-Risk TP53 Mutation Resulting in Significant Improv... PR Newswire
Last  Change Exchange
Market data is delayed by at least 15 minutes.
Markets Portfolio
    Symbol Lookup
    Latest Story
    Actinium Highlights Ability of Iomab-B to Overcome High-Risk TP53 Mutation Resulting in Significant Improvement in Overall Survival in Patients with Active Relapsed Refractory AML at the European Bone Marrow Transplant Annual Meeting
     PR Newswire

    Iomab-B led bone marrow transplant produced high rates of complete remission and durable complete remission regardless of TP53 mutation status in patients age 55 and above with high-risk active relapsed or refractory acute myeloid leukemia

    Full Story →

    Headline News
    Actinium Announces Iomab-B Phase 3 SIERRA Trial Results Demonstrating Survival Benefit in High-Risk Relapsed or Refractory Acute Myeloid Leukemia Patients with TP53 Mutations Accepted for Oral Presentation at the 50th European Bone Marrow Transplant Annual Meeting
    8:01a ET April 1 '24 PR Newswire
    Actinium Announces Clinical Trial to Study Iomab-ACT Targeted Radiotherapy Conditioning with Leading FDA Approved Commercial CAR T-Cell Therapy
    7:18a ET March 26 '24 PR Newswire
    Actinium Pharmaceuticals Launches Actinium-225 Focused Strategic Initiative to Leverage Proprietary Cyclotron Based Manufacturing Technology to Address Growing Market Demand
    7:30a ET March 11 '24 PR Newswire
    More News →
    Day  2.93%Week  10.08%Month  24.35%More Charting →
    April 23 '24. Markets Closed.
    Last $6.96
    Day change   2.93%$0.21
    Open $7.03
    Gap at open $0.14
    Previous close $7.17
    Trading volume 185,256
    10 Day avg vol. 318,313
    Shares out. 29.4Mil
    Market cap. $204.6Mil
    Trading activity Below Avg.
    Previous data from yesterday, April 22 '24.

    Historical Price Performance
    3 month   36.74% 
    6 month   25.63% 
    1 year   25.88% 
    2 year   1.46% 

    Earnings
    Previous 12m -$1.84
    Next 12m Estimate -$1.92
    P/E ratio 3.8x
    Revenue 0Mil

    Market data provided by News provided by


    This site is published in the United States for U.S. residents only. The services offered within this site are available exclusively through our U.S. Financial Advisors. Stifel Nicolaus Financial Advisors may only conduct business with residents of the state in which they are properly registered. The information on this website is not an offer to sell or a solicitation of an offer to buy, any security, nor shall any such security be offered or sold to any person in any jurisdiction in which such offer, solicitation, purchase or sale may not lawfully be made.
    Important Disclosures | Privacy Notice | HIPAA Policy | Use of Information Policy | Business Continuity | Canada Trade Matching Statement

    Stifel, Nicolaus & Co., Inc. Member NYSE, FINRA, and SIPC.
    Stifel Nicolaus Canada Inc., is a member of CIPF/FCPE and IIROC
    Copyright © 2024 All rights reserved.